ArticlePloS one2015
MiR-203 suppresses ZNF217 upregulation in colorectal cancer and its oncogenicity.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.The Journal of clinical investigation · 2020Trial
- Timing Expression of miR203a-3p during OA Disease: Preliminary In Vitro Evidence.International journal of molecular sciences · 2023Article
- Interferon regulatory factor 5‑induced upregulation of zinc‑finger protein 217 promotes pancreatic carcinoma progression.Molecular medicine reports · 2022Article
- Article
- ZNF488 Promotes the Invasion and Migration of Pancreatic Carcinoma Cells through the Akt/mTOR Pathway.Computational and mathematical methods in medicine · 2022Article
- Roles of miRNAs in Colorectal Cancer: Therapeutic Implications and Clinical Opportunities.Advanced pharmaceutical bulletin · 2021Review
- ZNF217: the cerberus who fails to guard the gateway to lethal malignancy.American journal of cancer research · 2021Review
- Implication ofMolecular cancer therapeutics · 2020Article
- LINC02595 promotes tumor progression in colorectal cancer by inhibiting miR-203b-3p activity and facilitating BCL2L1 expression.Journal of cellular physiology · 2020Article
- Limonoid compounds from Xylocarpus granatum and their anticancer activity against esophageal cancer cells.Thoracic cancer · 2020Article
- Targeting deubiquitinating enzyme USP26 by microRNA-203 regulates Snail1's pro-metastatic functions in esophageal cancer.Cancer cell international · 2020Article
- Long non-coding RNA CTBP1-AS2 enhances cervical cancer progression via up-regulation of ZNF217 through sponging miR-3163.Cancer cell international · 2020Article
- Retraction: Hypoxia-Inducible MiR-210 Is an Independent Prognostic Factor and Contributes to Metastasis in Colorectal Cancer.PloS one · 2020Article
- Retraction: MiR-203 Suppresses ZNF217 Upregulation in Colorectal Cancer and Its Oncogenicity.PloS one · 2020Article
- Article
- MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targetingOncotarget · 2019Article
- MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma.Clinical & experimental metastasis · 2017Article
- MicroRNA-203 predicts human survival after resection of colorectal liver metastasis.Oncotarget · 2017Article
- miR-203 as a novel biomarker for the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis.OncoTargets and therapy · 2017Article
- Elevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress.Oncotarget · 2016Article
Corrections and comments
- Retraction · 2020-12-17Concerns/Issues about Data · Duplication of/in Image · Error in Image ·
- Retracted
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc finger protein 217 (ZNF217) is essential for cell proliferation and has been implicated in tumorigenesis. However, its expression and exact roles in colorectal cancer (CRC) remain unclear. In this study, we demonstrated that ZNF217 expression was aberrantly upregulated in CRC tissues and associated with poor overall survival of CRC patients. In addition, we found that ZNF217 was a putative target of microRNA (miR)-203 using bioinformatics analysis and confirmed that using luciferase reporter assay. Moreover, in vitro knockdown of ZNF217 or enforced expression of miR-203 attenuated CRC cell proliferation, invasion and migration. Furthermore, combined treatment of ZNF217 siRNA and miR-203 exhibited synergistic inhibitory effects. Taken together, our results provide new evidences that ZNF217 has an oncogenic role in CRC and is regulated by miR-203, and open up the possibility of ZNF217- and miR-203-targeted therapy for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.